Joint with: Antibodies as Drugs: Innovative Formats, Design and Engineering

Better treatments are urgently needed for a range of devastating brain diseases, including prevalent neurodegenerative diseases, brain tumors and metastases, and rare genetic conditions. One major challenge in development of experimental CNS disease therapies is the lack of efficient tailored strategies for their delivery to the brain and spinal cord. This is the only conference to focuses entirely on scientific and technological advances and challenges in delivering new therapies, across a wide range of modalities, to appropriate compartments in the CNS.

The conference will spur multidisciplinary interactions and collaborations between scientists and trainees from academia, government and industry, including a wide range of biotech and biopharmaceutical companies. Importantly, participants include basic, translational and clinical scientists from diverse backgrounds, bridging fields of drug delivery, neuroscience, bioengineering, drug discovery and development.  Collectively these diverse perspectives will generate innovative insights and new directions to finally tackle this enormous challenge in medicine.